Urgent recall of 9,200 cucumber packs over fears they contain salmonella
PennRose Farms, LLC, is recalling 1,152 cases of its five-pound mesh bags of cucumbers, which amount to 9,216 individual units.
The affected bags have the logos of PennRose Farms and Restaurant Depot, and were packaged from May 2 to 5. They have the UPC code 841214101714 and the lot numbers 48-122, 48-123, 48-124, 48-125.
They were shipped to Restaurant Depot distribution centers in five states: Florida, Georgia, Illinois, New Jersey and Ohio.
PennRose Farms initiated the recall on Wednesday after its supplier, Fresh Start Produce Sales, notified it that Bedner Growers was recalling the cucumbers for possibly contamination. PennRose Farms had repacked some of the items in mesh bags.
Consumers are advised not to eat the cucumbers and throw them away immediately. Distributors, retailers and restaurants have been instructed to destroy them.
Anyone who has been served the cucumbers 'should be notified of the potential health concern', stated a notice from the US Food and Drug Administration (FDA) on Thursday.
Consumers with concerns should contact their healthcare providers. Those with questions can reach out to PennRose Farms, which is based in Wellington, Florida.
The cucumbers are the only item from PennRose Farms under the recall. More Trending
Salmonella is 'an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems', according to the FDA.
Healthy people infected with salmonella can experience symptoms including diarrhoea with or without blood, abdominal pain, vomiting, nausea and fever.
In rare, more serious cases, the salmonella organism can enter the bloodstream and cause arterial infections, arthritis and endocarditis.
It comes just weeks after Williams Farms Repack LLC recalled thousands of packs of its tomatoes sent to 14 states, over fears of salmonella contamination.
Get in touch with our news team by emailing us at webnews@metro.co.uk.
For more stories like this, check our news page.
MORE: Who is Elias Rodriguez? DC 'shooter' could face death penalty for killing Israel embassy staff
MORE: Trump administration blocks Harvard from enrolling foreign students
MORE: Famous talent agent among the dead in San Diego private jet crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
7 hours ago
- Reuters
US FDA approves Ionis' drug for rare genetic disorder
Aug 21 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' (IONS.O), opens new tab drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder. The drug, Dawnzera, is approved to prevent symptoms of a rare genetic disease called hereditary angioedema (HAE) in adults and pediatric patients over 12 years old. The condition causes frequent attacks of severe swelling in various parts of the body, including the hands, feet, genitals and face. Dawnzera will be available in the U.S. in the coming days, the company said. HAE is estimated to affect about 7,000 patients in the U.S., according to Ionis.
Reuters
13 hours ago
- Reuters
J&J to invest $2 billion to boost US manufacturing as drug tariffs loom
Aug 21 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Thursday it would invest $2 billion in North Carolina as it aims to expand its U.S. manufacturing presence amid looming drug import duties proposed by President Donald Trump's administration. Major drugmakers, including Eli Lilly (LLY.N), opens new tab and AstraZeneca (AZN.L), opens new tab, have also committed to shell out billions of dollars to scale up their U.S. footprint in response to Trump's efforts, including tariff threats. Earlier this month, Trump said he plans to impose phased-in tariffs for the pharmaceutical sector, which could start small and eventually rise to 250%. J&J said on Thursday it has reached a 10-year agreement with Tokyo-based contract drug developer Fujifilm Diosynth for its more than 160,000-square-foot manufacturing facility in Holly Springs, North Carolina, which would create about 120 new jobs. Fujifilm in April had signed a more than $3 billion deal with Regeneron (REGN.O), opens new tab to manufacture and supply drug products for the U.S.-based company at its North Carolina facility for a span of 10 years. J&J would also announce plans for additional manufacturing facilities in the U.S. and the expansion of current U.S. sites in the coming months. The healthcare conglomerate had said in March it would raise U.S. investments by 25% to more than $55 billion over the next four years, including a separate plant in Wilson, North Carolina.
Scottish Sun
13 hours ago
- Scottish Sun
‘Natural alternative' to fat jabs found – and it could help you lose 17% of your body weight
Plus, everything you need to know about the Mounjaro price hike - and how to beat it WEIGH HEY! 'Natural alternative' to fat jabs found – and it could help you lose 17% of your body weight Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) MANY weight loss interventions, such as gastric bypass surgery and fat jabs, can be seen as invasive or being on negative side effects. For people looking for a natural alternative to shedding the pounds, scientists have developed edible microbeads. Sign up for Scottish Sun newsletter Sign up 1 Edible microbeads were shown to reduce body weight by 17 per cent, in a new study Credit: Getty The microbeads, made from green tea polyphenols, vitamin E and seaweed, when consumed, bind to fats in the gastrointestinal tract. And preliminary results from tests carried out in a new study found this approach to weight loss may be safer and more accessible than surgery or pharmaceuticals. 'Losing weight can help some people prevent long-term health issues like diabetes and heart disease,' said Yue Wu, a graduate student at Sichuan University. 'Our microbeads work directly in the gut to block fat absorption in a noninvasive and gentle way.' Read more on fat jabs WEIGH IN How quickly weight piles back on after stopping fat jabs - and 2 danger points Weight gain is caused by genetic and lifestyle factors, including eating a high-fat diet. So, Wu and her colleagues wanted to target the fat absorption process with their weight-loss intervention, but avoid negative side effects. She said: 'We want to develop something that works with how people normally eat and live." The team created the tiny plant-based beads that spontaneously form through a series of chemical bonds between the green tea polyphenols and vitamin E. The beads were then coated in a natural polymer derived from seaweed to protect them from acid in the stomach. Once ingested, this protective polymer coating expands, the the green tea polyphenols and vitamin E compounds bind to and trap partially digested fats in the intestine. Weight Loss Jabs - Pros vs Cons With the microbeads being nearly flavourless, the researchers foresee them being easily integrated into people's diets. The researchers assessed the microbeads as a weight-loss treatment in rats. They were placed into three groups - those which were fed a high-fat diet either with or without microbeads and those which were fed a normal diet for 30 days. The rats fed the high-fat diet and microbeads were found to have lost 17 per cent of their total body weight, while rats in the other groups didn't lose weight. Wu and her team have now started working with a biotechnology company to manufacture the plant-based beads. 'All the ingredients are food grade and FDA-approved, and their production can be easily scaled up,' said Yunxiang He, Sichuan University associate professor and co-author on Wu's presentation. They've also initiated a human clinical trial in collaboration with the West China Hospital of Sichuan University. 'This represents a major step toward clinical translation of our polyphenol-based microbeads, following our foundational results,' said Wu. 'We have officially enrolled 26 participants in our investigator-initiated trial, and we anticipate that preliminary data may become available within the next year.'
